

This PANNA newsletter will also be available at the website: [www.pannastudy.com](http://www.pannastudy.com)

A newsletter will be issued once per 4 months to update you on the status of the study and inclusions.

**Centres**

All centres in *The Netherlands; UK; Italy; Germany; Belgium; Ireland; Spain* are open for inclusion.

*Canada*: ethics approval.


**List of compounds under investigation**

**panna**

Etravirine, Intelence, ETV  
 Emtricitabine, Emtriva or FTC  
 Tenofovir, Viread, TDF  
 Atazanavir, Reyataz, ATV  
 Fosamprenavir, Telzir, FPV  
 Darunavir, Prezista, DRV  
 Tipranavir, Aptivus, TPV  
 Indinavir, Crixivan, IDV  
 Raltegravir, Isentress, RAL  
 Enfuvirtide, Fuzeon, T-20  
 Maraviroc, Celsentri, MVC  
 Efavirenz, Stocrin, EFV\*  
 \*UK/Ireland only

**Inclusions**

66 subjects signed informed consent.



**Emtricitabine / tenofovir arms closed now!**

Just a reminder: patients on tenofovir / emtricitabine as the only compounds of the PANNA list cannot be included anymore. Atazanavir and darunavir are still open. Until we have 16 evaluable patients.

**CROI poster**

The first results of atazanavir, darunavir and ritonavir will be presented as a poster at the CROI 2012 in Seattle.

If you would like to receive the abstract you can contact Angela.

**Sample shipments**

Shipments via World Courier have been done for most sites now.

Thank you all!

**CRFs**

Angela will need data collected in the CRFs to prepare the CROI poster. She will contact you to send copies of the CRFs (by normal mail).

**Amendment**

In January 2012 an amendment will be issued to add rilpivirine to the list of ARVs under study.

**Plans**

We plan to submit an abstract to the HIV-PK workshop (tenofovir data). Abstract(s) will be sent to you for comments prior to submission. The first publications are expected in 2012.

**Have a nice holiday season!**



Angela and David

Angela Colbers  
 Project manager  
 E-mail: [A.Colbers@akf.umcn.nl](mailto:A.Colbers@akf.umcn.nl)  
 Radboud University Nijmegen Medical Centre, Internal postal code 864,  
 Department of Pharmacy,  
 P.O. Box 9101, 6500 HB Nijmegen  
 Phone: + 31 (0)24 - 361 64 05  
 Fax: + 31 (0)24- 366 87 55